Elenagen is under clinical development by CureLab Oncology and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elenagen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elenagen overview

Elenagen is under development for the treatment of triple negative breast cancer, ovarian cancer, lung cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, renal cancer, Inoperable stomach cancer (gastric cancer), glioblastoma, metastatic uterine cancer, pancreatic cancer, melanoma, age related macular degeneration and neurodegenerative diseases. The drug candidate is a DNA vaccine encoding p62/SQSTM1 plasmid. It is administered by intramuscular route. It was also under development for appetite disorder.

CureLab Oncology overview

CureLab Oncology (CureLab) is a biotechnology company that develops anti-cancer biologics and clinical trails. The company is headquartered in Boston, Massachusetts, the US.

For a complete picture of Elenagen’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.